Gilead Sciences Inc. (NASDAQ:GILD) received a $108.00 target price from Piper Jaffray Cos. in a report issued on Thursday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target suggests a potential upside of 32.73% from the company’s previous close.
GILD has been the subject of several other reports. Barclays PLC reissued an “overweight” rating on shares of Gilead Sciences in a report on Thursday, July 28th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. RBC Capital Markets set a $105.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Morgan Stanley dropped their price objective on Gilead Sciences from $107.00 to $103.00 and set an “equal weight” rating for the company in a research note on Thursday, May 26th. Finally, Berenberg Bank initiated coverage on Gilead Sciences in a research note on Thursday. They issued a “buy” rating for the company. Nine analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $105.26.
Gilead Sciences (NASDAQ:GILD) opened at 81.37 on Thursday. The stock has a 50 day moving average price of $79.46 and a 200 day moving average price of $85.89. The firm has a market cap of $107.38 billion, a price-to-earnings ratio of 7.14 and a beta of 1.06. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the consensus estimate of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period last year, the firm earned $3.15 EPS. Equities research analysts expect that Gilead Sciences will post $11.76 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.31%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.
In related news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total value of $9,444,960.00. Following the completion of the sale, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at $98,747,309.79. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $83.12, for a total value of $166,240.00. Following the completion of the sale, the executive vice president now directly owns 63,122 shares of the company’s stock, valued at $5,246,700.64. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in GILD. Searle & CO. raised its position in Gilead Sciences by 1.5% in the first quarter. Searle & CO. now owns 14,570 shares of the biopharmaceutical company’s stock valued at $1,371,000 after buying an additional 220 shares during the period. Webster Bank N. A. raised its position in Gilead Sciences by 6.8% in the first quarter. Webster Bank N. A. now owns 26,811 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,707 shares during the period. Banced Corp raised its position in Gilead Sciences by 20.5% in the first quarter. Banced Corp now owns 15,179 shares of the biopharmaceutical company’s stock valued at $1,395,000 after buying an additional 2,583 shares during the period. Capital Asset Advisory Services LLC bought a new position in Gilead Sciences during the first quarter valued at approximately $1,690,000. Finally, Franklin Street Advisors Inc. NC raised its position in Gilead Sciences by 6.2% in the first quarter. Franklin Street Advisors Inc. NC now owns 217,411 shares of the biopharmaceutical company’s stock valued at $19,971,000 after buying an additional 12,758 shares during the period. 77.94% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.